Cite
HARVARD Citation
Lheureux, S. et al. (2022). Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. Journal for immunotherapy of cancer. 10 (3), p. . [Online].